| 2016-10-12 08:07:21|
AMAG 08:07 10/12 10/12/16
AMAG Pharmaceuticals achieves key milestones in Makena, Feraheme programs
AMAG Pharmaceuticals announced that it has achieved two key milestones in its next generation development programs. The definitive pharmacokinetic study and the comparative pain study for the Makena subcutaneous auto-injector program have been initiated with the first patient dosed. The enrollment of patients in the Feraheme Phase 3 label expansion trial for the treatment of iron deficiency anemia, or IDA, has surpassed approximately two-thirds of the total target enrollment of 2,000 patients, resulting in the acceleration of the estimated supplemental new drug application, or sNDA, filing date to mid-2017.